Ovarian cancer
Adoptive therapy opening new possibilities even when chemotherapy standards are exhausted.
About the disease
Ovarian cancer often relapses and forms resistance to chemotherapy.
Adoptive cellular immunotherapy offers an alternative mechanism of impact on the tumor.
New vector
Works despite resistance to chemotherapy.
Process control
Inhibition of disease progression.
Gentle profile
Minimal toxic burden.
Extracorporeal immunotherapy
We move the immune 'training' process outside the body (ex vivo) — to an environment where we can create the conditions for training immunocompetent cells without creating any risk to your body.
Procedure
We draw your venous blood (up to 90 ml).
Activation (18 hours)
In the laboratory, using our proprietary technology (patents in Russia, the US, and the EU), we incubate the cells with immunomodulatory drugs and xenogeneic antigens. The cells receive a precise target.
Strike
We return the trained cells via subcutaneous injections. A powerful, multi-component immune response is developed.
Consolidation
The maintenance course forms long-term immunological memory, protecting against relapses for years.
Other directions
Discuss your situation
Leave your contact details. Our medical coordinator will contact you shortly to answer any questions.